Aspira Women's Health Files 8-K on Financials

Ticker: AWHL · Form: 8-K · Filed: Nov 14, 2024 · CIK: 926617

Aspira Women'S Health INC. 8-K Filing Summary
FieldDetail
CompanyAspira Women'S Health INC. (AWHL)
Form Type8-K
Filed DateNov 14, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-K, company-history

TL;DR

Aspira Women's Health filed an 8-K on Nov 14, 2024, updating its financial condition.

AI Summary

Aspira Women's Health Inc. filed an 8-K on November 14, 2024, to report on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.

Why It Matters

This filing provides investors with crucial, up-to-date information on Aspira Women's Health Inc.'s financial performance and operational status.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing with no immediate new material events disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Aspira Women's Health Inc., and it includes Financial Statements and Exhibits.

On what date was this 8-K filing reported?

The earliest event reported in this 8-K filing was on November 14, 2024.

What is the company's state of incorporation?

Aspira Women's Health Inc. is incorporated in Delaware.

What were some of the former names of Aspira Women's Health Inc.?

Aspira Women's Health Inc. was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.

What is the company's Standard Industrial Classification code?

The company's Standard Industrial Classification code is 2835, for IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.

Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-11-14 08:02:09

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: November 14, 2024 By: /s/ John Kallassy John Kallassy, Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing